Medexus Pharmaceuticals Inc.
MEDXF
$2.05
-$0.03-1.44%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.56% | -17.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.56% | -17.46% | |||
| Cost of Revenue | -14.83% | -23.98% | |||
| Gross Profit | 9.05% | -12.41% | |||
| SG&A Expenses | -0.07% | 10.97% | |||
| Depreciation & Amortization | -0.41% | 38.72% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.11% | -4.45% | |||
| Operating Income | 393.10% | -107.67% | |||
| Income Before Tax | 181.03% | -186.25% | |||
| Income Tax Expenses | 148.06% | -240.14% | |||
| Earnings from Continuing Operations | 193.31% | -175.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 193.31% | -175.44% | |||
| EBIT | 393.10% | -107.67% | |||
| EBITDA | 55.78% | -62.02% | |||
| EPS Basic | 185.56% | -162.96% | |||
| Normalized Basic EPS | -80.00% | -88.79% | |||
| EPS Diluted | 185.56% | -162.96% | |||
| Normalized Diluted EPS | -80.00% | -88.79% | |||
| Average Basic Shares Outstanding | 8.97% | 19.97% | |||
| Average Diluted Shares Outstanding | 8.97% | 19.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||